Consensus EyePoint, Inc.

Stocks

EYPT

US30233G2093

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 06/08/2026 +04			5-day change	1st Jan Change
12.25 ^USD	+4.97%		+2.77%	-32.95%

06:47pm	EyePoint, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03:59pm	Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, vs. FactSet Est of $390,000	MT

Evolution of the Average Target: EyePoint, Inc.

Evolution of the Target Price: EyePoint, Inc.

Changes in Analyst Recommendations: EyePoint, Inc.

41b417d4690dc101.7xo3gZpN32kpKbWDMU_BU5H4QBVkdvhYS46Nm8vqkOQ.m25g5PQKqTxGBIHFHCWNMt2sKkMiG80rcr-777_Yp7C4Tk7VyH7qDllF7A~6730064feb25b57f73a5fd11cef86a7c

Analysts' recommendations: EyePoint, Inc.

08-04	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT
07-29	Mizuho Raises Price Target on EyePoint Pharmaceuticals to $39 From $36, Keeps Outperform Rating	MT
07-16	Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target	MT
07-01	Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating	MT
05-07	RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating	MT
03-05	Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating	MT
11-06	RBC Raises Price Target on EyePoint Pharmaceuticals to $39 From $28, Keeps Outperform, Speculative Risk	MT
15/10/25	Cooking oil, hot markets
14/08/25	Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating	MT
17/06/25	RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target	MT
16/05/25	Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating	MT
07/01/25	Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target	MT
16/10/24	Scotiabank Initiates EyePoint Pharmaceuticals at Sector Outperform With $18 Price Target	MT
28/08/24	Jefferies Initiates EyePoint Pharmaceuticals at Buy	MT
04/06/24	JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	MT
08/05/24	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	MT
07/05/24	Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating	MT
07/05/24	Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating	MT
15/02/24	Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	MT
22/01/24	JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target	MT
11/12/23	Capital One Starts Coverage on EyePoint Pharmaceuticals with Overweight Rating, $44 Price Target	MT
07/12/23	Mizuho Ups Price Target on EyePoint Pharmaceuticals to $30 From $20, Citing 'Resoundingly Positive' Data for Lead Asset EYP-1901, Reiterates Buy Rating	MT
02/11/23	HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $25 From $27, Keeps Buy Rating	MT
02/11/23	Mizuho Initiates EyePoint Pharmaceuticals With Buy Rating, Price Target is $20	MT
14/06/23	JonesTrading Initiates EyePoint Pharmaceuticals at Buy With $26 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EYEPOINT, INC.					+247.04%
	ELI LILLY AND COMPANY					+14.46%
	JOHNSON & JOHNSON					+6.59%
	ABBVIE INC.					+11.64%
	ROCHE HOLDING AG					+1.74%
	NOVARTIS AG					+0.05%
	ASTRAZENECA PLC					+33.89%
	AMGEN INC.					-8.46%
	NOVO NORDISK A/S					+3.12%
	GILEAD SCIENCES, INC.					+16.19%
	Average					+32.63%
	Weighted average by Cap.					+9.72%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.67USD

Average target price

40.50USD

Spread / Average Target

+247.04%

High Price Target

68.00USD

Spread / Highest target

+482.69%

Low Price Target

20.00USD

Spread / Lowest Target

+71.38%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Mizuho Securities
Stifel Nicolaus
Chardan Research
RBC Capital Markets
Citigroup
Scotiabank
JPMorgan Chase
Baird
Capital One Securities
HC Wainwright
JonesTrading Institutional Services
Guggenheim
Cowen
Cantor Fitzgerald
B. Riley